US 7,538,128 B2
Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them
Abraham Thomas, Navi Mumbai (India); Gopalan Balasubramanian, Sholinganallur (India); V. S. Prasadarao Lingam, Navi Mumbai (India); and Daisy Manish Shah, Dadar (India)
Assigned to Glenmark Pharmaceuticals S.A., La Chaux-de-Fonds (Switzerland)
Filed on Feb. 15, 2007, as Appl. No. 11/675,180.
Application 11/675180 is a division of application No. 11/250195, filed on Oct. 12, 2005, granted, now 7,205,323.
Application 11/250195 is a continuation of application No. PCT/IB2005/002204, filed on Jul. 26, 2005.
Claims priority of provisional application 60/635266, filed on Dec. 10, 2004.
Claims priority of provisional application 60/618102, filed on Oct. 12, 2004.
Claims priority of application No. 1096/MUM/2004 (IN), filed on Oct. 14, 2004; and application No. 1332/MUM/2004 (IN), filed on Dec. 14, 2004.
Prior Publication US 2007/0238728 A1, Oct. 11, 2007
Int. Cl. A61K 31/4192 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/41 (2006.01); A61K 31/4196 (2006.01); A61K 31/4178 (2006.01); A61K 31/4155 (2006.01); A61K 31/4025 (2006.01); A61K 31/4015 (2006.01)
U.S. Cl. 514—359  [514/365; 514/372; 514/381; 514/383; 514/397; 514/406; 514/422; 514/423] 47 Claims
 
1. A method of inhibiting DPP-IV in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of formula (I)

OG Complex Work Unit Drawing
wherein:
Y is —S(O)m, —CH2—, CHF, or —CF2;
m is 0, 1, or 2;
X is a bond, C1-C5 alkyl, or —C(═O)—;
the dotted line [----] in the carbocyclic ring represents an optional double bond;
R1 is CN, or a substituted or unsubstituted heteroaryl ring or substituted or unsubstituted heterocyclic ring, wherein the ring is a five-membered ring having at least one nitrogen atom;
R2 is hydrogen, nitrile (—CN), or COOH; or
a tautomeric form, stereoisomer, enantiomer, diastereomer, N-oxide, or pharmaceutically acceptable salt thereof.